Mitragynine

Kratom Popularity Soars in Europe Thanks to Nectar Leaf's Famous Kratom Tea Infusions

Retrieved on: 
Thursday, June 17, 2021
Psychoactive drugs, Food and drink, Opioids, Antidepressants, Antidiarrhoeals, Euphoriants, Mitragyna speciosa, Naucleeae, Tea, Coffee, Mitragynine

With offices now in Barcelona, Spain, Nectar Leaf EU is delivering the benefits of their natural products to European consumers.

Key Points: 
  • With offices now in Barcelona, Spain, Nectar Leaf EU is delivering the benefits of their natural products to European consumers.
  • The biggest hit for Nectar Leaf was their introduction of single serve kratom tea bags .
  • You can read more about them here:
    Consumers have been raving about Nectar Leaf kratom tea's simple brewing process as well.
  • Their kratom coffee, kratom tea, capsules , extracts , and CBD products are truly second to none.

American Kratom Association: HHS Rescinds Scheduling Recommendation For Kratom But FDA Failed To Notify The Public For 2 ½ Years

Retrieved on: 
Thursday, January 28, 2021
Opioids, Indole alkaloids, Organic compounds, Psychoactive drugs, Antidiarrhoeals, Euphoriants, Mitragyna speciosa, Drugs, Mitragynine, 7-Hydroxymitragynine

In the HHS letter to the Drug Enforcement Administration (DEA) HHS recommended that "mitragynine and 7-hydroxymitragynine not be controlled at this time, either temporarily or permanently, until scientific research can sufficiently support such an action."

Key Points: 
  • In the HHS letter to the Drug Enforcement Administration (DEA) HHS recommended that "mitragynine and 7-hydroxymitragynine not be controlled at this time, either temporarily or permanently, until scientific research can sufficiently support such an action."
  • HHS concluded that "there is a significant risk of immediate adverse public health consequences to potentially millions of users if kratom or its components are included in Schedule I."
  • The HHS letter outlined 5 specific criteria for "further analysis and public input regarding kratom" before any scheduling should be undertaken.
  • Since the issuance of the recission letter, additional compelling research has further undermined the FDA's claims on the safety and abuse potential for kratom.

ATAI Life Sciences takes on opioid crisis by acquiring Kures to develop novel therapeutics for opioid abuse

Retrieved on: 
Thursday, July 9, 2020
Psychoactive drugs, Euphoriants, Analgesics, Opioids, Organic compounds, RTT, Ethers, Indole alkaloids, Mitragynine

Additionally, Srinivas Rao, MD, PhD, Chief Scientific Officer of ATAI Life Sciences, has been appointed CEO of Kures.

Key Points: 
  • Additionally, Srinivas Rao, MD, PhD, Chief Scientific Officer of ATAI Life Sciences, has been appointed CEO of Kures.
  • Both mitragynine and KUR-101 are atypical opioid receptor modulators, boasting unique pharmacology that may make them safer than currently available opioids in treating pain.
  • Moreover, it is estimated that 8-12% of individuals prescribed opioids for chronic pain ultimately develop opioid use disorder.
  • "Kures is excited to have the resources and commitment of ATAI in advancing our promising therapeutic compounds," added Andrew Kruegel, CSO and co-founder of Kures.